PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1877388
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1877388
The Nanomaterials In Personalized Medicine Market size was valued at US$ 355,456.34 Million in 2024, expanding at a CAGR of 11.5% from 2025 to 2032.
Nanomaterials in personalized medicine are nanoscale-engineered substances that interact with biological systems in a precise and controlled manner, allowing healthcare interventions to be tailored to an individual's specific genetic, molecular, or physiological characteristics. The rising prevalence of chronic diseases and advances in nanotechnology are major motivators, but high development costs and regulatory hurdles are significant impediments. However, opportunities exist for the development of novel nanomaterials with improved properties, the use of AI in drug discovery, and expansion into emerging markets. Strategic collaborations between pharmaceutical companies, biotechnology firms, and academic institutions are critical for overcoming these obstacles and realizing market potential.
Nanomaterials In Personalized Medicine Market- Market Dynamics
Increasing Demand for Personalized Medicine Fueling the Market Growth
The rising demand for personalized medicine is expected to drive the growth of nanomaterials in the personalized medicine market in the coming years. Personalized medicine is a medical approach in which treatments are tailored to individual patients based on genetic, environmental, and lifestyle factors in order to optimize outcomes and improve care. The demand for personalized medicine is growing as genomic technologies advance, allowing for the precise identification of genetic variations and tailored treatments for individuals. Nanomaterials improve personalized medicine by allowing for targeted and patient-specific therapies, which improves treatment efficacy and safety. They enable targeted delivery of drugs, genes, or RNA, lowering side effects and improving therapeutic outcomes. According to the Personalized Medicine Coalition (PMC), a nonprofit organization based in the United States, the FDA approved 26 new personalized medicines in 2023, up from 12 in 2022. As a result, the growing demand for personalized medicine is driving the development of nanomaterials in the personalized medicine industry.
The worldwide market is segmented on the basis of Application Areas, End-users, Type of Nanomaterials, Technology Utilized, Formulation Type, and Region.
The Formulation Type segment is primarily categorized into Nanoparticles, Nanocrystals, Nanosuspensions, Nanoemulsions, and Nanoformulations for Targeted Delivery. Among which. Nanoparticles are a crucial segment in the nanomaterials market for personalized medicine, playing a vital role in targeted drug delivery, cancer treatment and diagnostics. Their ability to overcome biological barriers and deliver therapeutic agents precisely to diseased cells makes them an attractive solution for various medical applications. For instance, in April 2025, Marama Labs launched CloudSpec, an instrument that accelerates quantification of drug payloads in lipid nanoparticles, enabling precise RNA or DNA measurements within 15 seconds.
Based on Application Areas, Drug Delivery Systems are one of the most important segments of the Nanomaterials in Personalized Medicine market because nano-enabled carriers (particularly lipid nanoparticles, or LNPs) enable the precise, safe, and efficient delivery of personalized therapies-including mRNA, siRNA, and gene-editing agents-to the intended cells while protecting fragile nucleic acids and minimizing off-target effects. One compelling example is Acuitas Therapeutics, a pioneer in LNP delivery technology. At the ASGCT annual meeting in 2025, Acuitas presented preclinical data for next-generation LNPs with DARPin-conjugated ligands to direct mRNA payloads to T-cells, as well as repeat dosing safety and targeting beyond the liver. In May 2024, Aldevron announced a strategic partnership with Acuitas to deploy its LNP platform for mRNA sequence-to-vial manufacturing, significantly increasing capacity for personalized RNA therapies.
Nanomaterials In Personalized Medicine Market- Geographical Insights
Asia Pacific has a significant share of the Nanomaterials in personalized medicine Market, owing to strong government initiatives, expanding biotech infrastructure, and increased healthcare investment. Countries such as China, India, Japan, and South Korea are at the forefront, with national programs supporting nanotechnology research and precision medicine development. Rising disease prevalence, particularly in chronic and genetic conditions, drives up demand for personalized nanomedicines. The region's growing middle class, combined with improved access to advanced healthcare, promotes the use of nano-enabled diagnostics and therapeutics. Asia Pacific is becoming a key market for innovation and growth, with rapid expansion in R&D and commercial capacity.
Japan Nanomaterials In Personalized Medicine Market- Country Insights
Japan is emerging as a major hub for nanomedicine innovation, due to strong government R&D support and a well-established biotech infrastructure. The Japan Nanomedicine Society encourages collaboration among academia, industry, and healthcare to advance nanomaterial-based therapies for personalized medicine. In April 2024, Nanoform Finland formed a strategic partnership with Japanese pharmaceutical firm CBC Co., Ltd. to bring Nanoform's nanoparticle-engineering platform to Japan. The goal is to improve drug bioavailability and reduce doses for Japanese patients. Furthermore, the Innovation Center of NanoMedicine (iCONM) in Kawasaki is spearheading cutting-edge research: in mid-2025, a team of researchers developed a nanomedicine that delivers antisense nucleic acids to lymph nodes to suppress cancer metastases.
The competitive landscape for Nanomaterials in Personalized Medicine Market is moderately concentrated, with major players including Evonik Industries AG, OncoNano Medicine Inc., and Merck KGaA. Evonik is developing lipid-based nanocarriers for cancer treatments, whereas OncoNano Medicine focuses on gold nanoparticle platforms for precise drug delivery and imaging. Merck KGaA uses polymer-based nanomaterials for targeted gene therapy and personalized prophylactics. These companies compete to improve nanocarriers' biocompatibility, stability, and targeting capabilities. Strategic partnerships, clinical collaborations, and scale-up initiatives all contribute to innovation. As the demand for tailored treatments grows, companies prioritize R&D investment and commercialization strategies to maintain their position as leaders in precision nanomedicine.
In June 2023, Bayer AG, a German pharmaceutical and biotechnology company, has partnered with Acuitas Therapeutics Inc. to gain access to its lipid nanoparticle (LNP) delivery technology. This collaboration aims to advance Bayer's in vivo gene editing and protein replacement programs by utilizing Acuitas' lipid nanoparticle technology, which enables efficient and targeted RNA delivery, particularly to the liver. Acuitas Therapeutics Inc. is a Canadian biotechnology company that specializes in lipid nanoparticle (LNP) delivery systems, which are important nanomaterials for personalized medicine.
In September 2023, Evonik improved its parenteral drug delivery solutions with three new PLA-PEG di-block copolymers (RESOMER RP d) and a nanoparticle formulation service based on sonication technology. The copolymers are excellent for nanoparticle formation and controlled drug release applications. The new nanosonication process allows for cGMP production of nanoparticles, addressing production challenges in drug delivery.